The advent of glory to JMP Clinical trial safety evaluation

46-drug information Association (DIA) Conference in 2010 from 13 to 17, held in Washington DC.

During the Conference, the world's largest statistical software and service provider SAS company officially launched the company's latest software product, used to JMP Clinical effectively streamline the clinical trials of the safety evaluation of drug development process down. JMP statistical data exclusively with Clinical and graphics dynamic link of advanced features that allow users to select from various angles and exploration of drug safety data, and you can easily share the results. Through the powerful SAS ® Analytics module and interactive visual data discovery software the perfect integration of JMP, JMP Clinical can complete adverse events (adverse events), laboratory (labs), morbidity indicators (incidence indicators) and the course record (patient profiles) and other important areas of medicine analysis.

JMP Clinical's most attractive hot spot is it at a life science Analytics areas most trustworthy two names: JMP and SAS.

United States food and Drug Administration is JMP (FDA) more than 40 per cent of the medical review officer preferred analysis tools, SAS has become the pharmaceutical industry biometrics company analysis and reporting standards. The birth of JMP Clinical makes the majority of the communication more convenient, for example, early involvement in the analysis of safety data in clinical trials of medical assessors, epidemiologists, data monitoring, biometrics and biometric group, etc., as well as the later sponsor analysts and food and drug administration of assessment personnel, etc. On the user's requirements for statistical skills greatly reduced, because they are faced with a customized dialog window and flexible analysis options.

Desktop software JMP Clinical reception menu interface follow FDA report criteria logical order, the background system is automatically compatible with clinical data interchange standards Association (CDISC) requirements for data analysis and reporting (CDISC is the area of clinical analysis and reporting in the emerging global harmonization of standards).

As the world's first comprehensive analysis of the data model supported by CDISC (ADaM) data format tool software, JMP Clinical can help clinicians and bio statisticians and smoothly transition to modern medicines evaluation environment.

JMP Clinical assessment personnel will have more time to clinical trial data to model and predict the results, instead of wasting in data processing, and programming.

Its lively and intuitive dashboard feature both greatly simplifies analysis of drug safety, and also ensure strict compliance with all the statistics of level in the security field filter requirements. In addition, JMP Clinical also can significantly reduce false positives and reducing the adverse event reports of excessive risk. Use JMP Clinical, access the graphics behind the data is also very convenient, can also intervene in the event, and the results, such as clustering analysis.

United States Kili Te company (Gilead Sciences Inc) bioassay of senior director Steve Wong is the first Clinical JMP user, his use of feeling is: "Clinical clearly, JMP can help us speed up analysis of the drug approval process in the process of critical factors.

JMP developed a very interesting tool to carry out many complex data analysis, as we add more value. ”